Core Viewpoint - The article discusses the upcoming IPO of Xianweida Biotechnology Co., Ltd., which focuses on innovative therapies for obesity and related diseases, highlighting its product pipeline and financial background [2][5]. Business Overview - Xianweida Biotechnology, established in 2017, is in the pre-commercialization stage and specializes in developing innovative treatments for obesity and related conditions. The company aims to transform its proprietary technology into safe and effective solutions for sustainable weight loss and the treatment of complications [5]. - The core product, Enoglutide Injection (XW003), is expected to be the first cAMP-biased GLP-1 receptor agonist launched in China for treating obesity and type 2 diabetes, with commercialization anticipated in 2026 after completing two BLA applications [5]. Product Pipeline - Besides XW003, key products include: - XW004: An oral GLP-1 receptor agonist with higher bioavailability, currently preparing for Phase II clinical trials, showing up to 6.8% weight loss in 6 weeks during Phase I trials [8]. - XW014: An oral small molecule cAMP-biased GLP-1 receptor agonist in Phase I clinical trials, demonstrating up to 5.6% weight loss over 43 days with fewer gastrointestinal side effects [8]. - XW015/XW016X: Amylin analogs in the clinical application stage, showing potential in diabetes and obesity treatment with milder gastrointestinal side effects compared to GLP-1 [8]. - Other pipeline products include XW019, a monthly biological injection in early research, and XW020, a long-acting injectable peptide drug expected to start Phase I trials by the end of 2026 [8]. Shareholder Structure and Financing - The major shareholder, Dr. Pan Hai, holds approximately 28.28% of the shares. Other investors include Tencent, IDG, Meituan, and several venture capital firms [9]. - The company has undergone multiple financing rounds since its inception, with significant increases in post-money valuations, reaching approximately 4.67 billion RMB in the latest round [9].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Hangzhou Sciwind Biosciences Co., Ltd.* 杭州先為達生物科技股份有限公司 (A joint stock company incorporated in the People's Republi ...

香 港 聯 合 交 易 所 有 限 公 司 與 證 券 及 期 貨 事 務 監 察 委 員 會 對 本 申 請 版 本 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 意 見，並 明 確 表 示 概 不 就 因 本 申 請 版 本 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損失承擔任何責任。 Hangzhou Sciwind Biosciences Co., Ltd.* 杭州先為達生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的要求而刊發， 僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知悉、 接納並向本公司、其保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章《公 司（清 盤 及 雜 項 條 文）條 例》呈 交 香 港 公 司 註 冊 處 處 長 登 記 前，本 公 ...